Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda and Lenvima in advanced hepatocellular carcinoma
NCT03713593Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2018
- Primary completion
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 21
01
Overview
A Phase 3 trial of pembrolizumab in hepatocellular carcinoma (HCC), sponsored by Merck & Co.. Started Dec 2018; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03713593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03713593.